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Abstract: Biomarkers provide certain values for diagnosis, monitor treatment efﬁ  cacy, or for the development of novel 
therapeutic approach for particular diseases. Thus, the identiﬁ  cation of speciﬁ  c of biomarkers for speciﬁ  c medical problems, 
including malignant diseases may be valuable in medical practice. In the study, we have used the Wilms’ tumor gene (WT1) 
as a biomarker to evaluate its expression in local adult patients with newly diagnosed acute leukemia, including both acute 
myeloid and lymphoid leukemias (AML and ALL).
Aim: To investigate WT1 gene expression in adult patients with acute leukemia at diagnosis. 
Methods: Eighteen patients with acute leukemia diagnosed at Singapore General Hospital, Singapore, between September, 
2004 and July, 2005 were included in this study. There were ﬁ  fteen AML and three ALL cases aged from 18 to 71 years old. 
Total RNA and DNA was extracted from peripheral blood mononuclear cells (PBMCs). Expression of WT1 was detected 
by nested reverse-transcription polymerase chain reaction (Nested RT-PCR). K562, and 3T3 cells were used as positive- and 
negative-controls. The results were revalidated using real-time PCR. HLA-A genotyping was performed using sequence 
speciﬁ  c oligonucleotide polymorphism (SSOP) analysis. 
Results: WT1 gene was exclusively expressed in all eighteen, including three ALL and ﬁ  fteen AML, patients. In contrast 
with WT1 gene, the HLA-A genotyping was remarkably heterogeneous in these patients. 
Conclusions: WT1 gene expression was observed in local patients with acute leukemia at diagnosis. It may be used as a 
potential molecular marker for diagnosis, clinical progression of the diseases or monitoring the response to treatment, as 
well as a target for the development of novel therapeutic approaches.
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Introduction
Acute myeloid leukemia in adults is a common and lethal malignant disease. Despite the tremendous 
efforts in the improvement of treatment in recent years, the survival of acute leukemia in adults remained 
poor. The Wilms’ tumor (WT1) gene, located at chromosome 11p13 (1), was identiﬁ  ed as a gene respon-
sible for Wilms’ tumor, a kidney neoplasm of
 childhood (2). The WT1 gene is encoded by 10 exons with 
different transcripts that subjects to alternative splicing. WT1 gene encodes proteins isoforms with 
molecular masses ranging from 48 to 54 kDa with four zinc ﬁ  nger motifs. WT1 gene plays multiple and 
important roles in cell biology, such as cell and tissue development, cell proliferation, differentiation, 
and apoptosis (3,4). It has been classiﬁ  ed as a tumor suppressor gene—encoding a transcription factor. 
Expression of WT1 has been observed in different types of solid cancers, such as ovarian cancer, meso-
thlioma of the lung, melanoma, breast cancer, as well as in Wilms’ tumor (5,6). It has been reported 
that the Wilms’ Tumor Gene (WT1) is expressed in leukemia blasts, irrespective of the subtypes of acute 
leukemia (7,8, 9).
 Early report showed that WT1 antisense oligonucleotides could induce apoptosis in 
myeloid cell lines (10). In recent years, it has been found that WT1 could be used as a molecular marker 
to generate speciﬁ  c cytotoxic T cells (CTL) against leukemia cells (11). The anti-leukemia activity of 
WT1-induced CTLs are reported to be HLA-A restricted and has been used as adoptive immunotherapy 
in some small scale clinical trials in patients with acute leukemia (12). 
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The current study was designed to investigate   
the WT1 gene expression status in local adult 
patients with acute leukemia. It was believed that 
this was the ﬁ  rst such study ever reported from 
Singapore. We were also exploring the possible 
clinical application of WT1 as a molecular marker 
in adult patients with acute leukemia.
Materials and Methods
Sample collection and cell process
 Peripheral blood (PB) was collected from eighteen 
consecutive adult patients with acute leukemia at 
diagnosis with informed consents and the approval 
of hospital’s Ethics Committee. Diagnosis for each 
patient was made according to the FAB criteria 
(13). PB was also obtained from healthy volunteers 
and used as normal controls. Mononuclear cells 
(MCs) were isolated using Ficoll-Hypaque (Amer-
sham Pharmacia Biotech, Upsala, Sweden) density 
gradient and centrifugation with 2,000 RPM at 
20 
oC for 20 minutes. PBMCs were collected from 
the interface of the density gradient separation for 
RNA and DNA extraction. 
DNA and RNA puriﬁ  cation
Total RNA was isolated using the RNeasy kit 
(Qiagen, Valencia, CA, U.S.A.) according to 
manufacturer’s protocol. Genomic DNA was 
isolated from mononuclear cell using a QIAamp 
Blood Mini Kit according to the manufacturer’s 
instruction (Qiagen, Valencia, CA, U.S.A.). Total 
RNA was used for nested RT-PCR and real-time 
PCR while DNA was used for HLA typing assay.
Nested RT-PCR 
(reverse-transcription PCR)
One step nested reverse transcription polymerase 
chain reaction (Nested RT-PCR) was performed by 
using a one-step RT-PCR kit. (Qiagen, Valencia, 
CA, USA) WT1 exon 1–4 was amplified using 
forward (5′-CCTACCTGCCC AG CTGCCTC-3′) 
and reverse (5′-CTCCTAAGTTCATCTGATTCC-
3′) primers for 20 cycles (annealing temperature 
56 
oC), followed by nested PCR (forward: 5′-
AGAGCCAGCCCGCTATTCG-3′; and reverse: 
GGTCATGCATTCAAGCTGG-3′ primers) for 
30 cycles (annealing temperature 58 
oC). The 
expected size for the PCR ampliﬁ  cation was 284 
bp(11). 
 Ampliﬁ  cations were performed with the 
GeneAmp PCR system 9700 (Applied Biosystem, 
Foster City, CA, U.S.A.). 
Real-time PCR
cDNA synthesis reaction was performed with 1 µg 
of total RNA in a total volume of 20 µL containing 
200 units M-MLV (moloney murine leukemia virus) 
reverse transcriptase (Invitrogen, Carlsbad, CA, 
U.S.A.), 1x First-Strand Buffer (50 mM Tris-HCl 
(pH 8.3) 75 mM KCl, 3mM MgCl2), 1mM dNTPs, 
10 mM DTT, 5 mM random primers and incubated 
at 42 
oC for 1hr. The reaction was inactivated by 
heating 90 
oC for 10 min Real-Time PCR(14) was 
performed in a MicroAmp
 optical 96-well plate with 
4 µL of the cDNA solution,
 0.5 µl of forward and 
reverse primers, 8µL of dH2O and
 12.5 µL of 2X 
SYBR Green Mix (Qiagen, Valencia, CA, U.S.A.). 
The sequences of forward and reverse primers for 
the semi-quantitative measurement of WT1 expres-





The reaction mixture was heated at 50 °C for 
2 minutes and then at
 95 °C for 15 minutes to acti-
vate the polymerase. PCR was then performed
 using 
an ABI Prism 7700 Sequence Detector System 
(Applied Biosystem, Foster City, CA, U.S.A.) with 
40 cycles, one of which consisted of denaturation 
at 94 °C
 for 15 seconds, and annealing at 56 °C for 
30 seconds followed by extension at 72 °C for 
30 seconds. The WT1 mRNA was assessed using 
the relative standard curve method (15). 
HLA-typing analysis
20 to 30 ng of genomic DNA was ampliﬁ  ed using
 the 
Dynal RELI™ SSO HLA-A typing kit (Dynal Biotech 
GmbH, Hamburg, Germany). PCR was performed 
strictly following the manufacturer instructions. In 
brief: PCR was performed in a total volume of 50 µL 
with the following steps: 15 seconds at 95 °C, 
45 seconds at 60 
oC, 15 seconds 72 °C and hold for 
5 minutes at 72 
oC. The PCR was performed using 
the GeneAmp PCR system 9700 (Applied Biosystem, 
Foster City, CA, U.S.A.). The probe hybridization and 
strip detection were also carried out following the 295
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manufacture’s instructions (Dynal RELI™ SSO 
HLA-A Typing kit, Dynal Biotech, Germany). The 
HLA-A typing for the patient samples was interpreted 
using the pattern-matching
 program provided by 
Dynal (Dynal Biotech GmbH, Hamburg, Germany). 
HLA-A typing was performed in 15/18 (83.3%) 
patients and the results were shown in Table 1.
Results
Nested RT-PCR
A 284bp band for the exon 1–4 of WT1 gene was 
detected in all 18 patients. The nested RT-PCR 
results from selected patients (Patients 1 to 12 
shown in Table 1) are summarized in Figure 1. In 
comparison to normal PBMCs, WT1 mRNA was 
detected at higher levels in all 18 patients with 
acute leukemia (AML), including 3 patients with 
acute lymphoblastic leukemia (ALL) and 15 patients 
with acute myeloid leukemia (AML). However, 
no densitometry was applied to compare the inten-
sity of RT-PCR products in this study. 
Real-time PCR
Real-time PCR was performed as conﬁ  rmational 
experiments to verify the WT1 mRNA over expres-
sion in the patients with acute leukemia. The WT1 
mRNA levels from all 18 patients with acute leuke-
mias was 41.39 ± 36.20% in comparison to K562 
cells. Real-Time PCR results from 1 patient with 
ALL and 5 with AML are shown in Figure 2. The 
Ct values of the real-time PCR are indicated in the 
insert of Figure 2. 
HLA-A typing
Unlike the universal expression of WT1 gene, the 
HLA genotyping in this cohort of adult acute 
leukemia patients was heterogeneous. The results 
of HLA-A typing of 15/18 patients from this study 
were summarized in Table 1. Coincidentally, all 3 
patients with ALL showed identical HLA-A typing. 
The HLA-A typing appeared to be more heteroge-
neous in patients with AML. 
Although there was no correlation observed 
between subtypes of AML and HLA-A typing, it 
was noticeable that 7/12 (58.3%) AML patients 
(patients number 4, 5, 6, 7, 8, 9 and 11) showed 
HLA-A2 genotype. 
Discussion
WT1 gene has been shown to be universally 
expressed in various types of malignant blood 
disorders, such as acute leukemia, chronic granlo-
cytic leukemia, multiple myeloma, etc (16,17,18,19). 
A number of reports have shown that WT1 gene 
could be used as a molecular marker for diagnosis, 
Table 1. WT1 Expression Proﬁ  le and HLA-A Typing in Patients with Acute Leukaemia.
Patients  Acute Leukaemia (Sub-types)  WT1 Expression  HLA-A Typing
1 ALL  Yes  *A-03201
2 ALL  Yes  *A-03201
3 ALL  Yes  *A-03010
4 AML  (M2)  Yes  *A-020101
5 AML  (M1)  Yes  *A-020501
6 AML  (M2)  Yes  *A-020101
7 AML  (CGL  → AML)  Yes  *A-020501
8 AML  (M5b)  Yes  *A-020101
9 AML  (M5a)  Yes  *A-020501
10 AML  (M5)  Yes  *A-240201
11 AML  (M1)  Yes  *A-020101
12 AML  (M2)  Yes  *A-240201
13 AML  (M2)  Yes  *A-030101
14 AML  (M7)  Yes  *A-030101
15 AML  (M1)  Yes  *A-030101
16 AML  (M3)  Yes  NT
17 AML  (M4)  Yes  NT
18 AML  (3v)  Yes  NT
ALL:  Acute lymphoblastic leukaemia; AML: Acute myeloid leukaemia; CGL: Chronic granulocytic leukaemia; HLA: Human leukocyte 
antigen, only HLA haplotyping could be conﬁ  rmed in the patients. NT: Not tested. 296
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Figure 2. RT-PCR results from selected patients numbred in Table 1 which RT-PCR results shown in Figure 1.  The Ct values are provided 
as follows:
No.  Samples   Ct Value  No.  ID  Ct Value
1  Blank  40  9  Patient 6 (AML/M2)  22.13
3  Negative control (3T3)  39.82  11  Patient 7 (AML/GCL → AML)  24.1
2  Positive control (K562)  22.93  10  Patient 8 (AML/M5b)  22.03
4  Normal control  27.92  12  Patient 9 (AML/M5a)  25.67
5  Patient 1 (ALL)  21.1  13  Patient 10 (AML/M5)  21.44
6  Patient 2 (ALL)  23.01  14  Patient 11 (AML/M1)  23.52
7  Patient 4 (AML/M2)  21.95  15  Patient 12 (AML/M2)  23.22
8  Patient 5 (AML/M1)  24.14  16  Patient 13 (AML/M2)  20.62
284bp
500bp 
1     2    3      4      5     6     7     8     9   10   11   12   13   14   15   16    17 
Figure 1. Nested PCR for WT1 expression.
monitoring clinical progress in acute leukemia, and 
more importantly, as a molecular target for adop-
tive immunotherapy (8,9,10). 
The results from current study have demon-
strated that the WT1 gene was “universally” 
expressed at diagnosis in a small cohort of local 
adult patients (18/18) with acute leukemia, 
including both AML and ALL, regardless of 
lineages of the leukemia cell origin. The results are 
in consistent with that reported in the literature (16, 
17,18,19). However, follow-up study could not be 
performed, largely due to the small numbers of 
circulating residual leukemia blasts post-induction 
chemotherapy. 
By using a more sensitive method, i.e. real-
time PCR, we found that the WT1 mRNA was 
expressed at a lower level in the normal PBMCs 
(Figure 2). In contrast, the expression level in the 
leukemia cells was much higher than that in 
normal blood cells. This observation was similar 
to that reported previously (20,21,22). Although 
the sequence of the WT1 mRNA was not examined 
in the current study, it is likely that the WT1 gene 
related to leukemia to be a wild type rather than 
mutation (23). 
The current study has shown that HLA-A typing 
was heterogeneous in adult acute leukemia patients. 
Although all three ALL patients showed identical 297
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HLA-A typing (Table 1), this was likely to be a 
coincidental observation and it could not draw any 
conclusion between a particular HLA allele and 
leukemogenesis in adulthood acute lymphoblastic 
leukemia. In comparison to ALL, the HLA-A 
typing in AML patients was more heterogenous. 
HLA-A2 was seen in 7/12 (58.3%) of the AML 
samples that had been HLA-A typed. However, no 
correlation between HLA-A typing and WT1 
mRNA levels in AML was observed. The results 
of HLA-A typing would be helpful for further 
evaluating the anti-leukemia activity in the cyto-
toxic T-lymphocyte (CTL) to be generated using 
leukemia cells from the patients. Studies in recent 
years by a number of reports have demonstrated 
that the WT1 protein-induced speciﬁ  c anti-leukemia 
activity by cytotoxic T lymphocytes (CTL) was 
HLA-A2-restricted.
 Colony formation by normal 
bone marrow cells
 of HLA-A2-positive patients 
were not inhibited by the WT1 leukemia-speciﬁ  c
 
CTL (10, 24, 25
 ). All these reports have 
demonstrated that WT1 proteins or peptides could 
be used as molecular targets for the development 
of speciﬁ  c cell based anti-leukemia therapy. WT1 
peptides as vaccine for anti-leukemia immunotherapy 
will be evaluated in our local patients in the 
future.
A recent report by Hossain et al has described 
the assessment of different WT1 transcripts, 
especially a 2.3 Kb short WT1 transcript (sWT1) 
which encodes a protein of ∼35–37 kDa, was over-
expressed in leukemia (26).
 Further study should 
be embarked to elucidate the WT1 isoforms in our 
patient population.
In conclusion, WT1 gene was universally 
expressed in local adult patients with acute leukemia 
at diagnosis in Singapore. It may be used as a poten-
tial molecular marker for diagnosis, monitoring the 
clinical progress, the response to treatment, as well 
as a target for the development of novel therapeutic 
approaches.
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